Влияние стронция ранелата на частоту переломов тел позвонков при остеопорозе в зависимости от факторов риска

1. Беневоленская Л.И. «Российской ассоциации по остеопорозу 10 лет. Доклад на II конгрессе по остеопорозу» Остеопороз и остеопатии 2005 № 3 с. 2-3

2. Михайлов Е.Е., Беневоленская Л.И., Баркова Т.В. «Эпидемиологическая характеристика переломов конечностей в популяционной выборке лиц 50 лет и старше» «Остеопороз и остеопатии» 1998 № 2 с. 2-6

3. «Остеопороз. Диагностика, профилактика и лечение» (клинические рекомендации) под ред. Беневоленской Л.И., Лесняк О.М. Москва, «Геотар-Медиа» 2005

4. «Руководство по остеопорозу» под ред. Беневоленской Л.И. Москва Бином. Лаборатория знаний 2003 с

5. «American association of endocrinologists (AACE) medical guidelines for prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates fore 2003» Endocrinology Practice 2003 vol. 9, № 6 p. 544-564

6. Alvarez-Hernandes D. et al. «Influence of polymorphisms VDR and COLIA1 genes on the risk of osteoporotic fractures in aged men» Kidney Int. Supplement 2003 vol. 85 June p. S14-18

7. Brandstrom H. et al. «Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women» Ibid p. 18-24

8. Brown J.P., Josse R.G. «2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada» CMAJ 2002 vol. 167 №10 suppl. P. SI-S34

9. Canalis E., Hott M. et al. «The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro» Bone 1996 18 p. 517-523

10. Cortet B. et al. «Strontium ranelate: approach in postmenopau sal osteoporosis» Revue du rhmatisme 2005, 72, p 16-22

11. European Summary of product characteristics, European Medi cines Agency www.emea.eu.int.

12. Grynpas M.D., Marie P.J. «Effects of low doses of strontium on bone quality and quantity in rats» Bone 1990 11 p. 313-329

13. Harpavat M. et al. «Metabolic bone disease in inflammatory bowel disease» Journal Clinical Gastroenterology 2004 vol. 38 № 3 p. 218-224

14. Marie P.J., Garba M.T. et al. «Short-term effects of fluoride and strontium on bone formation and resorption in the mouse» Metabolism 1986 35 р. 547-551

15. McLean R.R. et al. «Homocysteine as a predictive factor for hip fracture in older person» N. Engl. Journal Medical 2004 Vol. 350, № 20, p. 2042-2049

16. Meunier P.J. et al. «The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis» The new England journal of medicine Jan. 29 2004, vol. 350, No 5, p. 459-469

17. Meunier P.J., Reginster J.Y. «Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis» Osteoporos In ter. 2003 14 (suppl. 3) p. 66-76

18. Moskalenko M.V. et al. «Analysis of association of Collal gene alleles with the development of osteoporosis» Genetics 2002 vol. 38 № 12 p. 1699-1703

19. Pierre J. Marie, Monigue Hott et al. «An uncoupling agent con taining strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rate» American Soci ety for bone and Mineral research June 2005, V. 20 № 6, p. 1065-1074

20. Reginster J.Y., Seeman E. et al. «Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with oste oporosis: Treatment Of Peripheral Osteoporosis (TROPOS) study» The Journal of clinical endocrinology and metabolism may 2005, vol. 90, № 5, p. 2816-2822

21. Roux C., Reginster J.Y., Fechtenbaum J., et al.: Vertebral fracture risk reduction with strontium renelate in women with post-menopausal osteoporosis is independent of baseline risk factors. // J. Bone Mineral Research, 2006, Online published January, 22 pp.

22. Sattler A.M. et al. «Novel aspects on RANK ligand and osteo protegerin in osteoporosis and vascular disease» Calcif. Tissue Interna tional 2004 vol. 74 № 1, p. 103-106

23. Scottish Intercollegiate Guidelines Network (SIGN) 71: Management of osteoporosis: a national clinical guideline, June 2003 (www.sign.ac.uk)

24. Van Meurs J.B. et al. «Homocysteine levels and the risk of oste oporotic fracture» Ibid p. 2033-2041

25. Van Staa T.P. et al. «Inflammatory bowel disease and risk of fracture» Gastroenterology 2003 vol. 125 № 6, p. 1591-1597